IP and Public Health patents on pharmaceutical products and access to medicines Giulio C. Zanetti, IDLO Beirut, May 2003.

Slides:

Advertisements

Similar presentations

Caribbean Central American Action (CCAA) Strengthening in the Third Border (CBI) CCA 27 th Annual Miami Conference on the Caribbean Basin Dr Rosanna Cooper,

Advertisements

TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac

WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies (19-23 September 2005) TRADE, TRIPS AND ACCESS TO MEDICINES Cecilia Oh Department.

DEVELOPING COUNTRIES AND IP: ACCESS TO HEALTH CARE EDUCATION MATERIALS Karen A. LeCuyer, Ph.D. University of Connecticut School of Law 30 May 2007.

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.

Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.

Legemiddeløkonomiseminar Karianne Johansen Legemiddelindustriforeningen, LMI 2. desember 2010.

National symposium on Competition law: Evolution and Transition, 2012 Competition Policy for IP Issues Pradeep S Mehta Secretary General, CUTS International.

Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,

Presentation to Civil Society meeting Lusaka 1 October 2013.

IP News 指導老師：李柏靜學生：黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.

Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.

1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.

IP for Scientists Universities Allied for Essential Medicines (UAEM) UC Berkeley.

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.

A very short introduction to patents & access to medicines.

TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.

Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.

The emergence of an Enforcement Agenda Intellectual Property Rights and Access to Essential Medicines: Challenges and Opportunities in Free Trade Agreement.

PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.

Colin McInnes Simon Rushton Owain Williams. From NHS to ‘Global Health’

Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.

International IP Regime and A2M : Role of BRICS K M Gopakumar TWN.

D OHA N EGOTIATIONS & I NDIA P resenters * E vgeniya Burova * M ohini Patel.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.

WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,

Data Exclusivity and Access to Medicines – Empirical Evidence Hearing European Parliament: EU-India Free Trade Agreement: What Future for Patients in Developing.

Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.

EXCLUSIVE MARKETING RIGHTS & MAIL-BOX APPLICATIONS BY Manish Kumar Prusty T. Harish.

Zimbabwe CSOs TRIPS and Access to medicines Aulline Mabika-Chapisa.

MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.

Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.

Sustainable Approaches to Opening Access to Medical Inventions James Love Wizards of OS Berlin 15 Sept 06.

ACCESS TO MEDICINES - POLICY AND ISSUES

© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.

UNCTAD/CD-TFT 1 IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade.

Washington D.C., USA, July 2012www.aids2012.org Methodology to Determine the Patent Status of Key ARVs and Other Essential Medicines: A Strategy.

DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN LESOTHO REPORT OF DAY 1 Botha Tiheli, Masello.

Presentation to Civil Society meeting Harare 21 January 2014.

Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,

The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.

Trade & Access to Medicines in India Centre for Trade & Development

Introduction: Intellectual Property Rights and its impact on access to medicines Anand Grover United Nations Special Rapporteur on Health East Africa Consultation,

Implications of the TRIPS Patent Policy Srividhya Ragavan University of Oklahoma Law Center.

TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.

AIDS DRUGS, NATIONAL EMERGENCY & CIPRO Srividhya Ragavan Nat. Academy For Legal Studies & Research.

Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.

1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.

International Intellectual Property Prof. Manheim Spring, 2007 Patent Compulsory Licensing Copyright © 2007.

TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).

Human Rights and Access to Medicines Sean Flynn AU, Washington College of Law Abuja, Nigeria, November 2008.

RAC Regulatory Affairs Certification

Understanding Health Care Policy

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

WTO and medicines: from Doha to Cancún

Geographical Indications

International IP Roundtable UNLV, 8 April Seizure of Goods in Transit

Intellectual Property Protection and Access to Medicines

PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES

Trade-related policies and access to medicines

Details of Potential Conflict

IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade Agreements.

Intellectual Property Rights in Medicines Procurement

Presentation transcript:

IP and Public Health patents on pharmaceutical products and access to medicines Giulio C. Zanetti, IDLO Beirut, May 2003

Why are medicines expensive? Because they are DIFFICULT, EXPENSIVE, TIME-CONSUMING to discover develop test obtain Govern. authorization

!!! Benefit for humanity !!! CONSEQUENCE: …the inventor is entitled to a reward (monopoly) necessary to encourage R & D DEVELOPMENT! !!! Benefit for humanity !!!

A B users humanity (to have new drugs) i.e. patients ART. 7 (TRIPS) « …balance of rights and obligations » between A B users pharmaceutical comp. (to recup. investments) humanity (to have new drugs) i.e. patients

Is the TRIPS Agreement the real problem? NO, because flexibility clauses in TRIPS 2) many countries are not (yet) bound by TRIPS 3) Doha Declaration

Are patents the real problem? NO, because most antiretrovirals are not patented no patent law no patents on drugs no application no registration 2) Even most basic drugs are not available/ affordable

REAL PROBLEM: LACK OF FINANCIAL RESOURCES TO CREATE A PROPER HEALTH CARE INFRASTRUCTURE for testing storing distributing monitoring increasing awareness/knowledge

POST-DOHA DEVELOPMENT AGENDA status of negotiations possible solutions

www.wto.org gzanetti@idlo.int